Navigation Links
Hard to Treat Diseases (HTDS) clinical trial protocol for MMR Vaccine expected Q2 2009

SHENZEN, China, March 27 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) Today after the market closed the company announced the clinical trial protocol for their MMR Vaccine is under preparation, and is expected to be approved by the end of the second quarter 2009.

The MMR Vaccine is a mixture of three live attenuated viruses administered via injection for immunization against measles, mumps, and rubella (also called German measles). It is generally administered to children around the age of one year, with a second dose before starting school (i.e. age 4/5).

Prior to the widespread use of a vaccine against measles, its incidence was so high that infection was felt to be inevitable. Today, it is widely used around the world, and since introduction of its earliest versions in the 1970s, more than 500 million doses have been administered in over 60 countries. The incidence rate has fallen to a low of less than 1% of people under the age of 30 in countries with routine childhood vaccination.

The company will provide further details as they become available.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

CONTACT: For medical and scientific dialogue inquiry only, please contact; For any corporate matters, readers should contact the company directly at

SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Microsurgery May Cut Swelling After Breast Cancer Treatment
2. Treatment Target for Herpes Pinpointed
3. Plastic Surgeon Allan Parungao, MD, FACS, Announces Clinical Trial of Juvderm Technique to Treat Root Cause of Midface Sagging, without Surgery
4. Individualized stroke treatment available for patients, though underutilized
5. New Guidelines for Treating Heart Failure
6. New OTC Allergy Treatment Available to Food Allergy Sufferers
7. Combating weight gain caused by antipsychotic treatments
8. Autism Study Finds Significant Benefit with Hyperbaric Treatment
9. NeuroVasx Receives CE Mark for cPAX Aneurysm Treatment System
10. Surveyed Experts Indicate that Biogen Idecs Adentri Has Advantages Over Nitroglycerin in the Treatment of Acute Heart Failure
11. Autism Website Relaunches to Offer Resources, Treatments and Hope for Families
Post Your Comments:
(Date:12/1/2015)... ... 01, 2015 , ... TCS Healthcare Technologies (TCS), a leading ... arenas, is pleased to announce that VIP Care Services, a Caprock Health Group ... ACUITY Complete Care™ Management to back their collaborative catastrophic case management initiatives. ACUITY ...
(Date:12/1/2015)... China (PRWEB) , ... December 01, 2015 , ... Nurotron ... result in its largest order to date. , The order will be from ... systems. Nurotron’s Venus Cochlear Implant System is an effective solution for children and adults ...
(Date:11/30/2015)... ... November 30, 2015 , ... Olympic ... Bennett are collaborating with brands across various categories through traditional and social media ... up an elite group of Gold Medal Moms who can connect with today’s ...
(Date:11/30/2015)... (PRWEB) , ... December 01, 2015 , ... ... Dale Jones as a 2015-2016 inductee into its VIP Woman of ... education. NAPW is the nation’s leading networking organization exclusively for professional women, boasting ...
(Date:11/30/2015)... VA (PRWEB) , ... November 30, 2015 , ... ... Research Foundation (Meso Foundation) released information for caregivers and held two webinars on ... are available on demand free of charge at . , With ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Die MEDTEC Japan 2016, ... Entwicklung und Herstellung medizinischer Geräte, findet ... in Tokyo ... Foto: ... --> ...
(Date:11/30/2015)... SINGAPORE , Nov. 30, 2015  QT Vascular ... Vascular", and together with its subsidiaries, TriReme Medical LLC ... global company engaged in the design, assembly and distribution ... of vascular disease, is pleased to announce that a ... Court of Appeals for the Federal Circuit ("Federal ...
(Date:11/30/2015)... 30, 2015 Diplomat Pharmacy, Inc. (NYSE: ... the Detroit Free Press as a Top Workplace , ... to work for in 2015. ... 100 winners annually, based on employee surveys rating company leadership, ... Workplaces are based solely on employee feedback. The survey is ...
Breaking Medicine Technology: